Zila awarded blocking patent for oral cancer test:
This article was originally published in Clinica
The US Patent and Trademark Office has granted Phoenix, Arizona-based Zila a patent covering the use of oxadine and thiazine dyes for detecting oral cancer by direct application to oral tissues. The company is developing OraTest, an oral rinse containing the dye toluidine blue for the detection of cancerous mouth lesions, but has had difficulty getting the product approved by the FDA (see Clinica No 842, p 13). The new patent will prevent other companies from developing a similar product using a dye from the same or comparable chemical family.
You may also be interested in...
The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.